The Latest Analyst Ratings For Legend Biotech
The Latest Analyst Ratings For Legend Biotech
传奇生物的最新分析师评级
In the preceding three months, 15 analysts have released ratings for Legend Biotech (NASDAQ:LEGN), presenting a wide array of perspectives from bullish to bearish.
在过去三个月中，共有15名分析师发布了关于传奇生物（纳斯达克股票代码为LEGN）的评级，提供了从看好到看淡的广泛观点。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级，展示了过去30天内不断变化的情绪，并将其与前几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $78.93, a high estimate of $90.00, and a low estimate of $60.00. Highlighting a 2.56% decrease, the current average has fallen from the previous average price target of $81.00.
分析师所分析的12个月股价目标提供了洞察力，平均目标为78.93美元，高估值为90.00美元，低估值为60.00美元。当前平均值降低2.56%，从之前的81.00美元的平均股价目标下降。
Interpreting Analyst Ratings: A Closer Look
解读分析师评级：更深入的了解
In examining recent analyst actions, we gain insights into how...
通过分析最近的分析师...
登录免费看全文
登录/注册